| Característica |
Objectiu de la convocatòria
The Technology Impact Award provides seed funding to address the gap between technology development and clinical application of cancer immunotherapies. These grants aim to encourage collaboration between technology developers and clinical cancer immunologists.
|
Característiques principals
The award focuses on areas where technological innovation stands to benefit the field and cancer patients most, and that will ultimately lead to effective next generation cancer immunotherapies. These technologies may include but are not limited to:
New bioinformatics methods or technologies that speed collection and analysis of large sets of patient-derived biological data
Computer simulations for modeling biological systems and responses to immunotherapy
Tools and methods that improve profiling of tumors to inform therapeutic strategies
Real-time visualizations of molecular and cellular activity to improve tracking of responses to immunotherapy
In vitro tissue culture systems that recapitulate the interactions between primary tumor cells and the immune system
|
Lloc de presentació
IMIM and PSMAR staff who need more information should contact::
Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.04.00.
Carol Barnwell: cbarnwell@imim.es Ext.: 1670
Marta López: mlopez4@imim.es Ext.: 1576
|
Convocatòria (URL)
https://www.cancerresearch.org/scientists/fellowships-grants/technology-impact-award
|
Informació addicional
The process for applying for a CLIP Grant consists of two parts:
Letter of Intent: Deadline 15 November 2023
Invited Application: Deadline 15 March 2024
|
Requisits
Applicants must hold a faculty appointment as a tenure-track assistant professor (or higher rank) at the time of award activation. If not, documentation from their institution must accompany the Letter of Intent indicating they will hold the position of assistant professor (or higher rank) by the time of award activation.
The grant will be awarded to a scientist who describes an extraordinarily novel, yet practical research plan that is creative and technically sophisticated.
Joint submissions from collaborators will also be considered. (The collaborators will share the award.) Each collaborator must meet the eligibility criteria.
Selected projects that meet their 12 and 24 month milestones may be eligible for follow-on funding that will enable the established proof-of-concept technology to be developed into a methodology that improves cancer immunotherapy research worldwide.
|
Dotació
$200.000
|
Durada
12-24 months
|
Documentació
Letters of intent must be submitted electronically at https://www.grantrequest.com/SID_205?SA=SNA&FID=35050
Supporting documentation:
Abstract of research in nontechnical English explaining the significance of the new technology platform and its impact on the field of cancer immunotherapy. Not to exceed 250 words.
An initial research concept (succinct description of the proposed research plan with specific aims and timelines, description of the how the proposed technology platform has the potential to transform the field of cancer immunotherapy), not to exceed 3 pages.
Brief description of your current research.
Curriculum vitae and bibliography (limit bibliography to past 5 years or publications relevant to proposed research).
If applicable, curriculum vitae for all group members, as well as a description of each member's research focus.
|